ALNYLAM PHARMACEUTICALS, INC. Logo

ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):
US72703U1025 (+1 more)
LEI:
Country:
United States of America
Address:
675 WEST KENDALL STREET, 2142 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan 4875
Medicon Hellas S.A. Logo
Develops, makes, and sells IVD products, analytical systems & software for healthcare providers.
Greece MEDIC
MEDICOX Co., Ltd. Logo
Developing new drugs and building a distribution platform for healthcare solutions.
South Korea 054180
Medicus Pharma Ltd. Logo
A clinical-stage holding company advancing novel drugs, biologics, and devices to market.
United States of America MDCX
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan 2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea 078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America MDWD

Talk to a Data Expert

Have a question? We'll get back to you promptly.